Universities Buy Into The Patent Chase

For being at the right place at the wrong time, Bernard Erlanger missed the road to riches back in 1957. The Columbia University microbiologist knew that he had helped pioneer a powerful technique for making antibodies to steroids, and he even suspected that it might have commercial applications. Indeed, the method is now commonly used for everything from controlling animal litter size to testing human hormonal disorders—and the paper Erlanger wrote has become one of the most cited in his

Written byRobert Buderi
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

For being at the right place at the wrong time, Bernard Erlanger missed the road to riches back in 1957. The Columbia University microbiologist knew that he had helped pioneer a powerful technique for making antibodies to steroids, and he even suspected that it might have commercial applications. Indeed, the method is now commonly used for everything from controlling animal litter size to testing human hormonal disorders—and the paper Erlanger wrote has become one of the most cited in history.

At the time, a company was anxious to pursue the method’s possibilities, but it wouldn’t proceed without a guarantee of exclusivity. And when the microbiologist and his three colleagues approached the dean of Columbia’s medical school about patenting the discovery, the notion was quickly squelched. “The dean said, ‘No, this is unethical. Biomedical material should not be patented,”’ sighs Erlanger.

“We chuckle and say ‘Boy, just think if the dean ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies